肽处理肿瘤治疗相关性腹泻的对比观察 醋酸奥曲肽与洛哌丁胺治疗.doc

请登录编辑部网站 或咨询编辑部邮箱：cndj@ 国产、进口奥曲肽处理肿瘤治疗相关性腹泻的对比观察 邱 红1，熊慧华1，胡广原1，汪锐2，唐曦3 1 华中科技大学同济医学院附属同济医院肿瘤科 湖北省武汉市 430030 2 武汉市第一医院肿瘤中心 湖北省武汉市 430022 3 荆州市中心医院肿瘤科 湖北省荆州市 434020 第一作者简介：邱红，女，1976-09-28生，江西贵溪人，2001年毕业于华中科技大学同济医学院，主治医师，从事肿瘤放化疗的综合治疗，专业研究方向为肿瘤综合治疗。 通讯作者：胡广原，430030，湖北省武汉市解放大道1095号，华中科技大学同济医学院附属同济医院肿瘤科，huguangyuan@，电话：027 作者贡献分布：此治疗观察项目由邱红及胡广原设计，病例选择由邱红、胡广原、熊慧华、汪锐及唐曦共同完成，数据统计分析由邱红完成。本论文写作由邱红及胡广原共同完成。 摘 要 目的：进行国产及进口奥曲肽（依普比善及善宁）治疗II级以上肿瘤治疗相关性急性腹泻的疗效及药物经济学分析。方法：138例放疗及化疗相关性II-III级腹泻患者列入本观察研究，66例接受善宁治疗、72例接受依普比善，（首剂均为100μg，皮下注射，t.i.d），连续治疗3天后判断疗效。结果：善宁组腹泻完全缓解率为75.8%，依普比善组为79.2%，没有显著性差异。依普比善治疗III级腹泻第2天及第3天用量剂量高于善宁组。善宁组治疗方案的成本效果分析值为1148.7，依普比善组为507.3。结论：依普比善与善宁处理肿瘤治疗相关性腹泻方面疗效相当，但依普比善更符合药物经济学原则。处理重度腹泻时提高依普比善剂量是合理选择。 关键词：肿瘤治疗；急性腹泻；奥曲肽 The Comparing Research of Domestic Otreotide and Sandostatin in the Treatment of Acute Diarrhea Related with Anti-tumor Therapy Qiu Hong 1，Xiong Huihua1，Hu Guangyuan1，Wang Rui2，Tang Xi3 1 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science Technology, Wuhan 430030, Hubei Province, China 2 Department of Oncology，The first Hospital, Wuhan 430022, Hubei Province, China 3 Department of Oncology, Centre Hospital, Jingzhou 434020, Hubei Province, China Abstract: Purposes: To explore and compare the potential efficacy of domestic octreotide (Yi pu bi shan) and sandostatin in the treatment of acute diarrhea related with anti-tumor therapy. Materials and Methods: One hundred and thirty-eight patients with grade II or III diarrhea were enrolled into this research. Sixty-six patients received the treatment of sandostatin, and seventy-two patients were given domestic octreotide (100μg, t.i.d). Their respective efficacy was justified after the continuous treatment for 3 days. Results: The complete remission rate of diarrhea in sandostatin group was 75.8%, while that in domestic octreotide group was 79.2%, and P0.05. The administration dose of domestic octreotide on the second and third day was sig